The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock
Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...
With a stock price of $3.32, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 10 Unrivaled Penny Stocks to Buy Now. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M
"For 2026, we are maintaining our cash operating expense guidance of less than $390 million." (CFO & President of Recursion UK Taylor). "We expect multiple clinical readouts over the next 12 to 18 ...
Recursion Pharmaceuticals (RXRX Quick Quote RXRX - Free Report) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.5 ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $117.5 million in its first quarter. The Salt Lake City-based company said it had a ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the ...
Recursion Pharmaceuticals (RXRX Quick Quote RXRX - Free Report) ended the recent trading session at $5.03, demonstrating a -1.57% change from the preceding day's closing price. This move lagged the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results